Skip to main content
TipRanks
Go Ultimate75% OFF

Corcept Therapeutics (HTD) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HTD Analyst Ratings

Strong Buy
4Ratings
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to Corcept Therapeutics in the past 3 months

HTD Stock 12 Month Forecast

CHF137.95▲(0.00% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is CHF 137.95 with a high forecast of CHF 143.98 and a low forecast of CHF 133.99. The average price target represents a ― change from the last price of ―.
Highest Price TargetCHF143.98Average Price TargetCHF137.95Lowest Price TargetCHF133.99

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CH:HTD
Price TargetArticle
H.C. WainwrightCHF137.32buy―Reiterated11/05/26
Canaccord GenuityCHF133.99buy―Reiterated11/05/26
Piper SandlerCHF137.32→CHF143.98buy―Reiterated11/04/26
Truist FinancialCHF41.61→CHF136.49buy―Initiated08/18/26
Wolfe ResearchCHF41.61sell―Reiterated07/29/26
UBSCHF59.92buy―Upgraded05/13/26
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corcept Therapeutics

3 Months
Edward Nash
Edward NashCanaccord Genuity
Success Rate24/36 ratings generated profit
67%
Average Return
+13.08%

Copying Edward Nash's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +13.08% per trade.

1 Year
Edward Nash
Edward NashCanaccord Genuity
Success Rate26/36 ratings generated profit
72%
Average Return
+43.54%

Copying Edward Nash's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +43.54% per trade.

2 Years
Edward Nash
Edward NashCanaccord Genuity
Success Rate30/36 ratings generated profit
83%
Average Return
+72.28%

Copying Edward Nash's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +72.28% per trade.

HTD Analyst Recommendation Trends

010203040Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for HTD
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy30025
Buy1010985
Hold00000
Sell22200
Strong Sell00000
total1512111010

In the current month, HTD has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HTD average Analyst price target in the past 3 months is 137.95.

HTD Financial Forecast

CHF-2CHF-1CHF0CHF1CHF2Q1 2026Q3 2026Q4 2026
HighCHF1.25
ConsensusCHF0.92
LowCHF0.78

HTD Earnings Forecast

Next quarter’s earnings estimate for HTD is CHF 0.92 with a range of CHF 0.78 to CHF 1.25. The previous quarter’s EPS was CHF 0.83. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.

CHF136.1MCHF192.2MCHF248.3MCHF304.4MCHF360.5MQ1 2026Q3 2026Q4 2026
HighCHF361M
ConsensusCHF327M
LowCHF306M

HTD Sales Forecast

Next quarter’s sales forecast for HTD is CHF 327.39M with a range of CHF 306.32M to CHF 360.55M. The previous quarter’s sales results were CHF 281.03M. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.

HTD Stock Forecast FAQ

What is CH:HTD’s average 12-month price target, according to analysts?
Based on analyst ratings, Corcept Therapeutics’s 12-month average price target is CHF137.95.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Corcept Therapeutics a Buy, Sell or Hold?
Corcept Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Corcept Therapeutics’s share price target?
The average share price target for Corcept Therapeutics is CHF137.95. This is based on 4 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF143.98, and the lowest forecast is CHF133.99. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about Corcept Therapeutics?
Corcept Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of Corcept Therapeutics?
To buy shares of CH:HTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.